What are the recommended methimazole dosing guidelines for adults with overt hyperthyroidism, including initial and maintenance doses, and special considerations for elderly, pregnant, and pediatric patients?

Methimazole Dosing for Hyperthyroidism

Adult Dosing

For adults with overt hyperthyroidism, initiate methimazole at 15 mg daily for mild disease, 30-40 mg daily for moderate disease, and 60 mg daily for severe hyperthyroidism, divided into three doses at 8-hour intervals, with maintenance doses of 5-15 mg daily. 1

Initial Dosing Strategy

• Mild hyperthyroidism: Start with 15 mg daily divided into 3 doses 1
• Moderate hyperthyroidism: Start with 30-40 mg daily divided into 3 doses 1
• Severe hyperthyroidism: Start with 60 mg daily divided into 3 doses 1

The FDA labeling provides clear stratification based on disease severity, though clinical studies suggest that 30 mg daily is more effective than 15 mg daily for severe cases (free T4 ≥7 ng/dL), normalizing thyroid function in 96.5% versus 86.2% of patients at 12 weeks 2. For patients with free T4 ≥5 ng/dL, methimazole 30 mg daily achieves normalization faster than lower doses 3.

Maintenance Dosing

• Target maintenance dose: 5-15 mg daily 1
• Duration: Treat for 12-18 months initially 4
• Monitoring: Check thyroid function tests every 2-4 weeks until stable, then periodically 5, 1
• Dose adjustment: When TSH rises, reduce methimazole dose 1

Long-Term Low-Dose Therapy

For patients who complete standard 12-18 month therapy and achieve stable euthyroidism on low-dose methimazole (2.5-5 mg daily), continuation of this low dose significantly reduces recurrence risk (11% vs 41% recurrence at 36 months) without adverse effects 6. This is particularly beneficial for patients under 40 years old who have higher recurrence risk 6.

---

Pediatric Dosing

For children with Graves' disease, initiate methimazole at 0.4 mg/kg/day divided into 3 doses at 8-hour intervals, with maintenance dosing at approximately half the initial dose. 1

Pediatric-Specific Considerations

• Initial dose: 0.4 mg/kg/day divided into 3 doses 1
• Maintenance dose: Approximately 0.2 mg/kg/day (half of initial dose) 1
• Treatment duration: 24-36 months recommended (longer than adults) 7
• Extended therapy: Consider treatment for 3 years or more 7
• Preferred drug: Methimazole is strongly preferred over propylthiouracil due to severe hepatotoxicity risk with PTU in children 1, 7

---

Pregnancy Considerations

Propylthiouracil should be used instead of methimazole during the first trimester of pregnancy due to teratogenic risk; switch to methimazole for the second and third trimesters. 1

Pregnancy-Specific Dosing Strategy

• First trimester: Switch from methimazole to propylthiouracil to avoid congenital malformations 1
• Second and third trimesters: Switch back to methimazole due to PTU hepatotoxicity risk 1
• Dosing goal: Use the lowest dose necessary to maintain free T4 or free thyroxine index in the high-normal range 5
• Monitoring frequency: Check free T4 or FTI every 2-4 weeks 5
• Dose reduction: Many pregnant women require decreasing doses as pregnancy progresses; some can discontinue therapy weeks to months before delivery 1

Thyroid Storm in Pregnancy

For thyroid storm, methimazole or propylthiouracil is part of standard treatment along with iodine, dexamethasone, and supportive measures 5. Treatment should not be delayed for laboratory confirmation 5.

---

Elderly Patients

While the FDA label does not specify different dosing for elderly patients 1, exercise caution with dose adjustments in elderly patients, particularly those with cardiac comorbidities 5. The rapidity of dose adjustment should be slower in elderly patients with arrhythmias or cardiac disorders 5.

---

Critical Safety Monitoring

Agranulocytosis Warning

Patients must be instructed to immediately report sore throat, fever, or signs of infection, as agranulocytosis is a life-threatening adverse effect. 1

• Obtain complete blood count with differential if symptoms develop 1
• Discontinue methimazole immediately if agranulocytosis suspected 1
• Risk is higher with 30 mg daily versus 15 mg daily (14.8% vs 7.5% discontinuation rate) 3

Other Monitoring Requirements

• Prothrombin time: Monitor before surgical procedures due to bleeding risk 1
• Liver function: Hepatotoxicity can occur 5
• Vasculitis: Instruct patients to report new rash, hematuria, decreased urine output, dyspnea, or hemoptysis 1
• Thyroid function: Monitor periodically; rising TSH indicates need for dose reduction 1

Drug Interactions

• Warfarin: Increased anticoagulant effect; monitor PT/INR closely 1
• Beta-blockers: May need dose reduction when patient becomes euthyroid 1
• Digoxin: May need dose reduction when patient becomes euthyroid 1
• Theophylline: May need dose reduction when patient becomes euthyroid 1

---

Dose Titration Approach

Use dose titration (adjusting methimazole dose to maintain euthyroidism) rather than block-and-replace regimens (high-dose methimazole plus levothyroxine), particularly in pediatric patients 7. This approach minimizes drug exposure and adverse effects.